{"id":"NCT01966120","sponsor":"Biofrontera Bioscience GmbH","briefTitle":"Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)","officialTitle":"A Randomized, Double-blind, Phase III, Multi-center Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) Versus Placebo in the Field-directed Treatment of Mild to Moderate Actinic Keratosis With Photodynamic Therapy (PDT) When Using the BF-RhodoLED® Lamp","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-10","primaryCompletion":"2014-09","completion":"2015-04","firstPosted":"2013-10-21","resultsPosted":"2016-12-19","lastUpdate":"2023-07-28"},"enrollment":87,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Actinic Keratosis"],"interventions":[{"type":"DRUG","name":"BF-200 ALA gel","otherNames":["Ameluz"]},{"type":"DRUG","name":"Placebo to BF-200 ALA gel","otherNames":[]},{"type":"PROCEDURE","name":"Photodynamic therapy with BF-RhodoLED","otherNames":["PDT"]}],"arms":[{"label":"BF-200 ALA gel","type":"ACTIVE_COMPARATOR"},{"label":"Placebo to BF-200 ALA gel","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of BF-200 ALA (Ameluz) versus placebo in the field-directed treatment of mild to moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED lamp.","primaryOutcome":{"measure":"Overall Patient Complete Response 12 Weeks After the Last Photodynamic Therapy (PDT)","timeFrame":"12 weeks after PDT 1 or 12 weeks after PDT 2 which might have been necessary because not all lesions were cleared after the first PDT","effectByArm":[{"arm":"BF-200 ALA","deltaMin":90.9,"sd":null},{"arm":"Placebo to BF-200 ALA","deltaMin":21.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":1,"countries":["Germany"]},"refs":{"pmids":["39666443"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":55},"commonTop":["Application site pain","Application site erythema","Application site pruritus","Application site scab","Application site exfoliation"]}}